JP7530360B2 - Tyk2阻害剤およびその使用 - Google Patents

Tyk2阻害剤およびその使用 Download PDF

Info

Publication number
JP7530360B2
JP7530360B2 JP2021530887A JP2021530887A JP7530360B2 JP 7530360 B2 JP7530360 B2 JP 7530360B2 JP 2021530887 A JP2021530887 A JP 2021530887A JP 2021530887 A JP2021530887 A JP 2021530887A JP 7530360 B2 JP7530360 B2 JP 7530360B2
Authority
JP
Japan
Prior art keywords
nitrogen
compound
sulfur
oxygen
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021530887A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022509260A5 (cg-RX-API-DMAC7.html
JP2022509260A (ja
Inventor
ジェレミー ロバート グリーンウッド,
クレッグ イー. マッセ,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2022509260A publication Critical patent/JP2022509260A/ja
Publication of JP2022509260A5 publication Critical patent/JP2022509260A5/ja
Priority to JP2024120957A priority Critical patent/JP2024160253A/ja
Application granted granted Critical
Publication of JP7530360B2 publication Critical patent/JP7530360B2/ja
Priority to JP2025283785A priority patent/JP2026053668A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021530887A 2018-11-30 2019-11-27 Tyk2阻害剤およびその使用 Active JP7530360B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024120957A JP2024160253A (ja) 2018-11-30 2024-07-26 Tyk2阻害剤およびその使用
JP2025283785A JP2026053668A (ja) 2018-11-30 2025-12-26 Tyk2阻害剤およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862773620P 2018-11-30 2018-11-30
US62/773,620 2018-11-30
PCT/US2019/063510 WO2020112937A1 (en) 2018-11-30 2019-11-27 Tyk2 inhibitors and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024120957A Division JP2024160253A (ja) 2018-11-30 2024-07-26 Tyk2阻害剤およびその使用

Publications (3)

Publication Number Publication Date
JP2022509260A JP2022509260A (ja) 2022-01-20
JP2022509260A5 JP2022509260A5 (cg-RX-API-DMAC7.html) 2022-12-05
JP7530360B2 true JP7530360B2 (ja) 2024-08-07

Family

ID=70848642

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021530887A Active JP7530360B2 (ja) 2018-11-30 2019-11-27 Tyk2阻害剤およびその使用
JP2024120957A Pending JP2024160253A (ja) 2018-11-30 2024-07-26 Tyk2阻害剤およびその使用
JP2025283785A Pending JP2026053668A (ja) 2018-11-30 2025-12-26 Tyk2阻害剤およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024120957A Pending JP2024160253A (ja) 2018-11-30 2024-07-26 Tyk2阻害剤およびその使用
JP2025283785A Pending JP2026053668A (ja) 2018-11-30 2025-12-26 Tyk2阻害剤およびその使用

Country Status (8)

Country Link
US (2) US11053241B2 (cg-RX-API-DMAC7.html)
EP (1) EP3886843A4 (cg-RX-API-DMAC7.html)
JP (3) JP7530360B2 (cg-RX-API-DMAC7.html)
CN (1) CN113271938A (cg-RX-API-DMAC7.html)
AU (1) AU2019389025B2 (cg-RX-API-DMAC7.html)
CA (1) CA3120866A1 (cg-RX-API-DMAC7.html)
IL (1) IL283409B2 (cg-RX-API-DMAC7.html)
WO (1) WO2020112937A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4327809A3 (en) 2015-09-02 2024-04-17 Takeda Pharmaceutical Company Limited Tyk2 inhibitors and uses thereof
CN110300590A (zh) 2016-10-21 2019-10-01 林伯士拉克许米公司 Tyk2抑制剂及其用途
JP7619951B2 (ja) 2018-10-15 2025-01-22 武田薬品工業株式会社 Tyk2阻害剤およびその使用
WO2020112937A1 (en) 2018-11-30 2020-06-04 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
EP4269404A4 (en) * 2020-12-25 2024-12-04 Xizang Haisco Pharmaceutical Co., Ltd. KETOHEXOKINASE INHIBITORS AND USE THEREOF
EP4308556A4 (en) 2021-03-16 2025-02-19 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Amino heteroaryl compounds and compositions
KR20240111312A (ko) 2021-10-25 2024-07-16 카이메라 쎄라퓨틱스 인코포레이티드 Tyk2 분해제 및 이의 용도
TW202425965A (zh) * 2022-09-30 2024-07-01 日商科研製藥股份有限公司 縮環化合物及含有其之醫藥
CN115974751A (zh) * 2022-12-13 2023-04-18 山东能源集团新材料有限公司 一种吡拉西坦制备方法及系统
JP2026501940A (ja) * 2022-12-22 2026-01-19 プロテクト セラピューティクス リミテッド ピロロピリジンおよびピロロピリダジンに基づく化合物ならびにpkr阻害剤としてのその使用
EP4739694A2 (en) * 2023-07-03 2026-05-13 Blossomhill Therapeutics, Inc. Macrocyclic compounds and use as tyk2 inhibitors
US11891394B1 (en) 2023-09-06 2024-02-06 King Faisal University Pyrrolo[2,3-c][1,6]naphthyridine-8-carboxylic acid compounds as CK2 inhibitors
US11858935B1 (en) 2023-09-06 2024-01-02 King Faisal University Pyrrolo[2,3-c][1,7]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors
US11878978B1 (en) 2023-09-06 2024-01-23 King Faisal University Pyrrolo[2,3-c]quinoline compounds as CK2 inhibitors
CN117342955A (zh) * 2023-10-08 2024-01-05 盐城师范学院 一种制备4’-甲基-联苯-2-胺的方法
WO2025222103A1 (en) * 2024-04-19 2025-10-23 Raythera, Inc. Stat6 modulators and methods of uses thereof
WO2025264818A1 (en) * 2024-06-20 2025-12-26 Raythera, Inc. Stat6 modulators and methods of uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001512729A (ja) 1997-08-05 2001-08-28 ファイザー・プロダクツ・インク 神経ペプチドY受容体アンタゴニストとしての4−アミノピロ−ル(3,2−d)ピリミジン
WO2006011670A1 (ja) 2004-07-28 2006-02-02 Takeda Pharmaceutical Company Limited ピロロ[2,3-c]ピリジン化合物、その製造方法および用途
JP2017514838A (ja) 2014-05-01 2017-06-08 ノバルティス アーゲー Toll様受容体7アゴニストとしての化合物および組成物
WO2018031434A1 (en) 2016-08-08 2018-02-15 Merck Patent Gmbh Tlr7/8 antagonists and uses thereof
WO2018089695A1 (en) 2016-11-11 2018-05-17 Dynavax Technologies Corporation Toll-like receptor antagonist compounds and methods of use

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
US5650270A (en) 1982-02-01 1997-07-22 Northeastern University Molecular analytical release tags and their use in chemical analysis
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
OA12118A (en) 1999-12-10 2006-05-04 Pfizer Prod Inc PyrroloÄ2,3-dÜpyrimidine compounds.
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
KR100833371B1 (ko) 2001-04-27 2008-05-28 젠야쿠코교가부시키가이샤 헤테로시클릭 화합물 및 이를 유효 성분으로 하는 항종양제
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
MXPA05001766A (es) 2002-08-14 2005-08-19 Atugen Ag Uso de proteina quinasa n beta.
WO2004089925A1 (en) 2003-04-03 2004-10-21 Semafore Pharmaceuticals, Inc. Pi-3 kinase inhibitor prodrugs
ES2382377T3 (es) 2003-05-30 2012-06-07 Gemin X Pharmaceuticals Canada Inc. Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer
WO2005007623A2 (en) 2003-07-03 2005-01-27 The Trustees Of The University Of Pennsylvania Inhibition of syk kinase expression
LT2612862T (lt) 2004-05-13 2017-01-25 Icos Corporation Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
DK1753764T3 (da) * 2004-06-09 2009-02-16 Glaxo Group Ltd Pyrrolopyridin-derivater
US7449458B2 (en) 2005-01-19 2008-11-11 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
ES2493466T3 (es) 2005-05-12 2014-09-11 Abbvie Bahamas Ltd. Promotores de la apoptosis
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
HRP20140975T1 (hr) 2005-10-07 2014-11-21 Exelixis, Inc. Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze
WO2007053452A1 (en) 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
KR101533461B1 (ko) 2006-04-26 2015-07-02 에프. 호프만-라 로슈 아게 Pi3k저해제로 유용한 티에노[3,2-d]피리미딘 유도체
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
HUE029188T2 (en) 2007-03-12 2017-03-28 Ym Biosciences Australia Pty Phenylamino-pyrimidine compounds and their use
US8394794B2 (en) 2007-03-23 2013-03-12 Regents Of The University Of Minnesota Therapeutic compounds
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
MY165582A (en) 2008-03-11 2018-04-05 Incyte Holdings Corp Azetidine and cyclobutane derivatives as jak inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
HRP20220766T1 (hr) 2012-11-08 2022-09-16 Bristol-Myers Squibb Company Amidom-supstituirani heterociklički spojevi korisni kao modulatori il-12, il-23 i/ili ifn alfa odgovora
EP2922841B8 (en) 2012-11-08 2017-08-02 Bristol-Myers Squibb Company Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
ES2702126T3 (es) 2013-12-10 2019-02-27 Bristol Myers Squibb Co Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
US9340540B2 (en) 2014-02-28 2016-05-17 Nimbus Lakshmi, Inc. TYK2 inhibitors and uses thereof
TWI763722B (zh) * 2016-10-14 2022-05-11 美商林伯士拉克許米公司 Tyk2抑制劑及其用途
WO2020112937A1 (en) 2018-11-30 2020-06-04 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001512729A (ja) 1997-08-05 2001-08-28 ファイザー・プロダクツ・インク 神経ペプチドY受容体アンタゴニストとしての4−アミノピロ−ル(3,2−d)ピリミジン
WO2006011670A1 (ja) 2004-07-28 2006-02-02 Takeda Pharmaceutical Company Limited ピロロ[2,3-c]ピリジン化合物、その製造方法および用途
JP2017514838A (ja) 2014-05-01 2017-06-08 ノバルティス アーゲー Toll様受容体7アゴニストとしての化合物および組成物
WO2018031434A1 (en) 2016-08-08 2018-02-15 Merck Patent Gmbh Tlr7/8 antagonists and uses thereof
WO2018089695A1 (en) 2016-11-11 2018-05-17 Dynavax Technologies Corporation Toll-like receptor antagonist compounds and methods of use

Also Published As

Publication number Publication date
JP2024160253A (ja) 2024-11-13
US20200172540A1 (en) 2020-06-04
US20220106306A1 (en) 2022-04-07
AU2019389025A1 (en) 2021-06-17
WO2020112937A1 (en) 2020-06-04
EP3886843A4 (en) 2022-08-31
CA3120866A1 (en) 2020-06-04
US11053241B2 (en) 2021-07-06
IL283409A (en) 2021-07-29
CN113271938A (zh) 2021-08-17
AU2019389025B2 (en) 2025-07-24
JP2026053668A (ja) 2026-03-25
IL283409B1 (en) 2026-03-01
EP3886843A1 (en) 2021-10-06
JP2022509260A (ja) 2022-01-20
IL283409B2 (en) 2026-07-01
US11834449B2 (en) 2023-12-05

Similar Documents

Publication Publication Date Title
JP7498200B2 (ja) Tyk2阻害剤およびその使用
US11834449B2 (en) TYK2 inhibitors and uses thereof
JP7699052B2 (ja) Tyk2阻害剤およびその使用
US20230391797A1 (en) Tyk2 inhibitors and uses thereof
WO2021127283A2 (en) Irak degraders and uses thereof
AU2019360941A1 (en) TYK2 inhibitors and uses thereof
HK40055822B (en) Tyk2 inhibitors and uses thereof
HK40055822A (en) Tyk2 inhibitors and uses thereof
HK40009936B (en) Tyk2 inhibitors and uses thereof
HK40009936A (en) Tyk2 inhibitors and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231124

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240222

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240321

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240510

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240528

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240624

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240726

R150 Certificate of patent or registration of utility model

Ref document number: 7530360

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150